Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTUNYSE:CYBNNASDAQ:IPHANASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$8.95-1.0%$7.46$5.51▼$11.73$174.81MN/A47,231 shs129,997 shsCYBNCybin$6.99-1.0%$7.16$4.81▼$14.44$150.12M0.61237,103 shs145,994 shsIPHAInnate Pharma$1.98-1.5%$1.99$1.29▼$3.51$165.98M0.31185,067 shs29,165 shsTNYATenaya Therapeutics$0.49+6.6%$0.63$0.39▼$4.96$40.34M2.982.31 million shs3.29 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-1.00%+11.88%+11.88%-11.47%+894,999,900.00%CYBNCybin-1.83%-4.90%-0.29%-30.31%+1,590.45%IPHAInnate Pharma-1.49%+0.51%+9.39%+11.86%-19.51%TNYATenaya Therapeutics+6.64%+9.16%-23.42%-59.40%-88.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACYBNCybin1.5853 of 5 stars3.50.00.00.00.00.81.3IPHAInnate Pharma2.7189 of 5 stars3.85.00.00.01.81.70.0TNYATenaya Therapeutics3.7659 of 5 stars3.54.00.00.01.95.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.50129.05% UpsideCYBNCybin 3.00Buy$86.001,130.33% UpsideIPHAInnate Pharma 3.50Strong Buy$11.00455.56% UpsideTNYATenaya Therapeutics 3.00Buy$6.251,172.39% UpsideCurrent Analyst Ratings BreakdownLatest TNYA, ACTU, CYBN, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/24/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.004/22/2025ACTUActuate TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.003/31/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/28/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.503/17/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.003/13/2025CYBNCybinGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.003/13/2025TNYATenaya TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/12/2025TNYATenaya TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $5.003/12/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $9.003/11/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $5.00(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/A$10.83 per shareN/AIPHAInnate Pharma$12.63M13.14N/AN/A$0.69 per share2.87TNYATenaya TherapeuticsN/AN/AN/AN/A$2.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$24.75MN/A0.00∞N/AN/AN/AN/AN/ACYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/AIPHAInnate Pharma-$8.19MN/A0.00∞N/AN/AN/AN/AN/ATNYATenaya Therapeutics-$124.08M-$1.32N/AN/AN/AN/A-86.17%-71.14%5/13/2025 (Estimated)Latest TNYA, ACTU, CYBN, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025TNYATenaya Therapeutics-$0.18N/AN/AN/AN/AN/A3/17/2025Q4 2024TNYATenaya Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.681.68CYBNCybinN/A24.2424.24IPHAInnate Pharma0.922.92N/ATNYATenaya TherapeuticsN/A5.275.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/ACYBNCybin17.94%IPHAInnate Pharma0.16%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%CYBNCybin15.00%IPHAInnate Pharma31.89%TNYATenaya Therapeutics32.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1019.53 millionN/AN/ACYBNCybin5021.48 million17.96 millionNot OptionableIPHAInnate Pharma22083.83 million57.10 millionNot OptionableTNYATenaya Therapeutics11087.58 million53.27 millionOptionableTNYA, ACTU, CYBN, and IPHA HeadlinesRecent News About These CompaniesH.C. Wainwright maintains Buy on Tenaya Therapeutics stockApril 26 at 3:11 PM | investing.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%April 26 at 10:11 AM | aaii.comTenaya announces interim data from ongoing RIDGE studyApril 25 at 1:30 AM | markets.businessinsider.comTenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025April 24 at 2:07 PM | globenewswire.comTenaya Slashes a Third of Workforce to Fund Development of Cardio Gene TherapiesApril 1, 2025 | biospace.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest Down 22.1% in MarchApril 1, 2025 | marketbeat.comTenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from HC WainwrightApril 1, 2025 | marketbeat.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 11.06%April 1, 2025 | aaii.comTenaya data further builds TN-201 profile, says H.C. WainwrightApril 1, 2025 | markets.businessinsider.comTenaya says TN-201 well tolerated in Phase 1b/2 interim dataApril 1, 2025 | markets.businessinsider.comTenaya to lay off about one-third of staff, reveals heart gene therapy dataMarch 31, 2025 | endpts.comTenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual MeetingMarch 31, 2025 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by AnalystsMarch 30, 2025 | marketbeat.comSA Asks: Which small/mid-cap cardiology stocks are undervalued?March 28, 2025 | msn.comIs Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comWhat is Chardan Capital's Forecast for TNYA FY2025 Earnings?March 28, 2025 | marketbeat.comTenaya Therapeutics Publishes Positive Preclinical Data for TN-201 Gene Therapy Targeting MYBPC3-Associated Hypertrophic CardiomyopathyMarch 26, 2025 | nasdaq.comTenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in MarchMarch 25, 2025 | insidermonkey.comTop 3 Insider Stock Buys in March—Are They Still Good in April? (TNYA)March 25, 2025 | insidertrades.comTenaya Therapeutics publishes preclinical data on TN-201 in cardiac functionMarch 24, 2025 | markets.businessinsider.comTenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happyMarch 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Intel-Taiwan Semiconductor Alliance Fuels Turnaround HopesBy Jeffrey Neal Johnson | April 8, 2025View Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomBy Nathan Reiff | April 10, 2025View 3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomThe Ecosystem Edge: Joby's Competitive AdvantageBy Jeffrey Neal Johnson | April 4, 2025View The Ecosystem Edge: Joby's Competitive AdvantageGoodyear Gains Traction: Shares Climb as Key Catalysts AlignBy Jeffrey Neal Johnson | April 7, 2025View Goodyear Gains Traction: Shares Climb as Key Catalysts AlignTNYA, ACTU, CYBN, and IPHA Company DescriptionsActuate Therapeutics NASDAQ:ACTU$8.91 -0.13 (-1.44%) As of 04/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Cybin NYSE:CYBN$6.99 -0.07 (-0.99%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$7.24 +0.26 (+3.65%) As of 04/25/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Innate Pharma NASDAQ:IPHA$2.00 -0.01 (-0.50%) As of 04/25/2025 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Tenaya Therapeutics NASDAQ:TNYA$0.49 +0.03 (+6.64%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.50 +0.00 (+0.98%) As of 04/25/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
